Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2002-02-08
2008-03-11
Berch, Mark L. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C544S277000
Reexamination Certificate
active
07342021
ABSTRACT:
PDE4 inhibition is achieved by novel compounds of the Formula I:wherein R1and R2are as defined herein.
REFERENCES:
patent: 3917563 (1975-11-01), Meyer et al.
patent: 3919192 (1975-11-01), Meyer et al.
patent: 5013829 (1991-05-01), Nair et al.
patent: 5073559 (1991-12-01), Coates
patent: 5525606 (1996-06-01), Moschel et al.
patent: 5744473 (1998-04-01), Chasin et al.
patent: 5814651 (1998-09-01), Duplantier et al.
patent: 5864037 (1999-01-01), Chasin et al.
patent: 5935978 (1999-08-01), Fenton et al.
patent: 5939422 (1999-08-01), Cavalla et al.
patent: 6037470 (2000-03-01), Cavalla et al.
patent: 6040447 (2000-03-01), Cavalla et al.
patent: 6057445 (2000-05-01), Cavalla et al.
patent: 6211367 (2001-04-01), Cavalla et al.
patent: 6228859 (2001-05-01), Cavalla et al.
patent: 6310205 (2001-10-01), Chasin et al.
patent: 6316928 (2001-11-01), Chasin et al.
patent: 2003/0045533 (2003-03-01), Liu et al.
patent: 2004/0102460 (2004-05-01), Hopper et al.
patent: 2006/0052331 (2006-03-01), Koch et al.
patent: 2007/0093510 (2007-04-01), Tehim et al.
patent: 2 405 895 (1974-08-01), None
patent: 42 30 755 (1994-03-01), None
patent: 197 02 785 (1998-07-01), None
patent: 199 35 209 (2001-02-01), None
patent: 1 043 324 (2000-10-01), None
patent: 62-10085 (1987-01-01), None
patent: 62-240622 (1987-10-01), None
patent: 05-001066 (1993-01-01), None
patent: 10-72415 (1998-03-01), None
patent: 11-180982 (1999-07-01), None
patent: 11-189577 (1999-07-01), None
patent: 2000-72773 (2000-03-01), None
patent: 20000-72773 (2000-03-01), None
patent: WO 93/25517 (1993-12-01), None
patent: WO 94/14742 (1994-07-01), None
patent: WO 98/58901 (1998-12-01), None
patent: WO99/24432 (1999-05-01), None
patent: WO 99/29694 (1999-06-01), None
patent: WO 01/87281 (2001-11-01), None
patent: WO 02/098878 (2002-12-01), None
Chalmers (TiPS vol. 17, pp. 166-172 Apr. 1996).
“Hydroxamic acids” <http://www.iupac.org/goldbook/H02911.pdf> downloaded from the internet Jun. 30, 2006.
Grant & Hackh's Chemical dictionary, 5thedition, pp. 115, 220 (1987).
Thomas C. McKenzie et al., “The Gomberg-Bachmann Reaction of Purines”,J. Heterocyclic Chem., May-Jun. 1987, pp. 859-861, vol. 24.
Vasu Nair et al., “Novel, Stable Congeners of Antiretroviral Compound 2′, 3′-Dideoxyadenosine,”J. Am. Chem. Soc., 1989, pp. 8502-8504, vol. 111.
James E. Kelley et al., “Antirhinovirus structure-activity relationships of 6-substituted-9-(4-methybenzyl)-2-trifluoromethyl-9H-purines,”Eur. J. Med. Chem., 1990, pp. 131-135, vol. 25.
Jean-Jacques Bourguignon et al., “9-Benzyladenines: Potent and Selective cAMP Phosphodiesterase Inhibitors,”J. Med. Chem, 1997, pp. 1768-1770, vol. 40.
James L. Kelley et al., “6-(Alkylamino)-9-alkylpurines. A New Class of Potential Antipsychotic Agents,”J. Med. Chem., 1997, pp. 3207-3216, vol. 40.
Elisabeth Boichot et al., “Anti-Inflammatory Activities of a New Series of Selective Phosphodiesterase 4 Inhibitors Derived from 9- Benzyladenine,”The Journal Of Pharmacology And Experimental Therapeutics, 2000, pp. 647-653, vol. 292, No. 2.
V. Vair, “Hydrolysis of Dideoxgenated Purine Nucleosides: Effect of Modification o f the Base Moiety”,J. Org. Chem, 1990, pp. 3695-3697, vol. 55, No. 11.
H. Nagano et al., “Fluorine-Containing Potential Anticancer agents. II. Syntheses Trifuoromethylpurines and Trifluormethylthiazolopyrimidines”,J. Med. Chem., 1964, pp. 215-220, vol. 7, No. 2.
Vasu Nair et al., “Inhibition of mammalian adenosine deaminase by novel functionalized 2′, 3′-dideoxyadenosines”,Biochim. Biophys. Acta.1991, pp. 121-123, vol. 1078, No. 1.
Patent Abstracts of Japan, vol. 2000, No. 6, Sep. 22, 2000, JP 200 072773, Mar. 7, 2000.
Patent Abstracts of Japan, vol. 1999, No. 12, Oct. 29, 1999, JP 11 180982, Jul. 6, 1999.
Thomas C. McKenzie et al., “The Gomberg-Bachmann Reaction of Purines”,J. Heterocyclic Chem., May-Jun. 1987, pp. 859-861, vol. 24.
Vasu Nair et al., “Novel, Stable Congeners of Antiretroviral Compound 2′, 3′-Dideoxyadenosine,”J. Am. Chem. Soc., 1989, pp. 8502-8504, vol. 111.
Vasu Nair et al., “Synthesis Of Congeners Of Adenosine Resistant To Deamination by Adenosine Deaminase,”J. Chem. Soc Comm., 1989, pp. 876-879.
James L. Kelley et al., “Synthesis and Strcuture-Activity Relationships of 2-Substituted-6-(dimethylamino)-9-(4-methylbenzyl)-9H-purines with Antirhinovirus Activity,”J. Med. Chem., 1989, pp. 218-224, vol. 32.
James E. Kelley et al., “Antirhinovirus structure-activity relationships of 6-substituted-9-(4-methylbenzyl)-2-trifuloromethyl-9H-purines,”Eur. J. Med. Chem., 1990, pp. 131-135, vol. 25.
Roger J. Schilling et al., “A High-Throughput Assay For Cyclic Nucleotide Phosphodiesterases,”Analytical Biochemistry, 1994, pp. 154-158, vol. 215.
Donald V. Daniels et al., “A Semiautomated Method for the Assay of Cyclic Adenosine 5′-Monophosphate Phosphodiesterase,”Analytical Biochemistry, 1998, pp. 367-389, vol. 238.
Jean-Jacques Bourguignon et al., “9-Benzyladenines: Potent and Selective cAMP Phosphodiesterase Inhibitors,”J. Med. Chem, 1997, pp. 1768-1770, vol. 40.
James L. Kelley et al., “6-(Alkyamino)-9-alkylpurines. A New Class of Potential Antipsychotic Agents,”J. Med. Chem., 1997, pp. 3207-3216, vol. 40.
Hiroyuki Sawanishi et al., “Selective Inhibitors of Cyclic AMP-Specific Phosphodiesterase: Heterocycle-Condensed Purines”,J. Med. Chem., 1997, pp. 3248-3253, vol. 40.
J.E. Sounnes et al., “Proposal for Pharmacologically Distinct Conformers of PDE4 Cyclic AMP Phosphodiesterases”,Ceβ Signal, 1997, pp. 227-236, vol. 9, No. 3-4.
Mary Elizabeth Bach et al., “Age-related defects in spatial memory are correlated with defects in the late phase of hippocampal long term potentiation in vitro and are attenuated by drugs that enhance the cAMP signaling pathway”,Proc. Natl. Acad. Sci. USA, Apr. 1999, pp. 5280-5285, vol. 96.
Elisabeth Boichot et al., “Anti-inflammatory Activities of a New Series of Selective Phosphodiesterase 4 Inhibitors Derived from 9- Benzyladenine,”The Journal Of Pharmacology And Experimental Therapeutics, 2000, pp. 647-653, vol. 292, No. 2.
Japanese Patent Abstract No. 05-001066 dated Jan. 8, 1993.
Japanese Patent Abstract No. 62-240622 dated Oct. 21, 1987.
Japanese Patent Abstract No. 62-010085 dated Jan. 19, 1997.
T. J. Martin, “PDE4 Inhibitors—A Review of the Recent Patent Literature”, IDrugs, vol. 4, No. 3, 2001, pp. 312-338.
Japanese Patent Abstract No. 05-001066 dated Jan. 8, 1993.
Japanese Patent Abstract No. 62-240622 dated Oct. 21, 1987.
Japanese Patent Abstract No. 20000-072773, with partial translation.
Raboisson et al., “Design, synthesis and structure—activity relationships of series of 9-substituted adenine derivatives . . . ” Eur. J. Med. Chem., 38, 2003, pp. 199-214.
Reimund et al., “Anti-TNF-α Properties of New 9-Benzyladenine Derivatives with Selective . . . ”, Biochemical & BioPhysical, (2001), pp. 427-434.
Hess Hans-Jurgen Ernst
Hopper Allen
Liu Ruiping
Rong Yajing
Tehim Ashok
Berch Mark L.
Memory Pharmaceuticals Corp.
Millen White Zelano & Branigan P.C.
LandOfFree
Phosphodiesterase 4 inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Phosphodiesterase 4 inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Phosphodiesterase 4 inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3964456